Pharmacokinetics of Enoxaparin in Intensive Care Patients
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically
ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered
either as a continuous intravenous infusion or subcutaneous bolus once daily.
To investigate possible ongoing coagulation by coagulation markers during antithrombotic
therapy with standard doses of enoxaparin